The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Early & Long-Term Remission of Spondyloarthritis

Early & Long-Term Remission of Spondyloarthritis

July 16, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The results from a similarly designed trial in ankylosing spondylitis were more complex. In comparing a tight-control/treat-to-target strategy in axial SpA with usual care, Molto et al. did not find a statistically significant difference between treatment groups using the primary endpoint of the percentage of patients with a greater than 30% improvement on the ASAS-Health Index (ASAS-HI). However, the authors wrote that the tight-control/treat-to-target group did achieve more favorable secondary efficacy outcomes, had a similar safety profile and was more cost effective at one year than the group receiving usual care.5 These findings may indicate a role for treat-to-target and tight control approaches in ankylosing spondylitis management.

You Might Also Like
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
Explore This Issue
August 2021
Also By This Author
  • The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

Dr. Van den Bosch ended his talk with the concept of the DEER approach, which stands for dedicated, empathic and educated rheumatologist. This approach means rheumatologists should keep in mind such issues as mental health, socioeconomic factors, central pain sensitization syndromes, such as fibromyalgia, and comorbidities that may affect a patient’s likelihood to respond or not respond to treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is currently in practice with Skylands Medical Group, N.J.

References

  1. Vandendorpe AS, de Vlam K, Lories R. Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments. RMD Open. 2019 Jan 22;5(1):e000779. eCollection 2019.
  2. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005 Apr;52(4):1205–1215.
  3. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123–131.
  4. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A U.K. multi-centre, open-label, randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2489–2498.
  5. Molto A, López-Medina C, Van den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: Results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021 May 6:annrheumdis-2020-219585. Epub ahead of print.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: AS Resource Center, EULAR, patient care, spondyloarthritisIssue: August 2021

You Might Also Like:
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)